✅ URGE INCONTINENCE

⭐ 1. Core Problem (Always Score Marks)

• Cause: Detrusor overactivity → bladder contracts when it shouldn’t.
• Symptoms: Urgency, frequency, nocturia, urge leakage.

👉 If you remember “Overactive detrusor = sudden leakage,” you already get 40% marks.

⭐ 2. First-Line Treatment (Most Tested)

Anti-muscarinics (MAIN TREATMENT)

• Drugs: Oxybutynin, Tolterodine
• Target: M3 muscarinic receptors in detrusor muscle
• Effect:
• ↓ involuntary contractions
• ↑ bladder capacity
• ↓ urgency & leakage

👉 Blocking M3 = bladder relaxes = patient stops leaking.

⭐ 3. Doses You Must Know

Tolterodine

• IR 2 mg twice/day
• ER 4 mg once/day

Oxybutynin

• IR 2.5–5 mg three times/day
• ER 5–10 mg once/day

👉 ER forms cause fewer side effects.

⭐ 4. Side Effects (Very High Yield)

Why? Because they block muscarinic receptors everywhere.

• Dry mouth
• Constipation
• Blurred vision/dry eyes
• Dizziness
• Elderly: cognitive impairment risk

👉 Think “DRY + SLOW.”

⭐ 5. Contraindications (Examiners LOVE these)

Do NOT use in:

• Urinary retention
• Gastric retention / severe GI obstruction
• Uncontrolled narrow-angle glaucoma

👉 Anything already “tight or blocked” → anti-muscarinic will worsen it.

⭐ 6. If Anti-muscarinics Fail (Second-line)

• Mirabegron (β3 agonist) – relaxes detrusor without anticholinergic SE
• Botox intradetrusor
• Posterior tibial nerve stimulation / sacral neuromodulation

👉 Mirabegron = best alternative when dryness/constipation is a problem.

🔥 SUPER-SUMMARY (What the exam actually wants)

Urge incontinence = detrusor overactivity.

First-line treatment = anti-muscarinics (Tolterodine/Oxybutynin).

MOA = M3 blockade → relaxes detrusor → ↑ capacity → ↓ urgency.

Side effects = DRY + SLOW (dry mouth, constipation, blurred vision).

Avoid in urinary retention & glaucoma.

Mirabegron = best alternative.

✅ DULOXETINE IN STRESS INCONTINENCE

⭐ 1. Core Concept (Most Important)

• Duloxetine = SNRI (Serotonin–Noradrenaline Reuptake Inhibitor).
• Use: Stress urinary incontinence (SUI).
• Main Action:

Increases urethral sphincter tone by increasing serotonin & noradrenaline at the pudendal nerve → sphincter contraction.

👉 SUI = weak sphincter → duloxetine strengthens the sphincter.

⭐ 2. Mechanism (Exam Favourite)

• SNRIs ↑ serotonin & noradrenaline in Onuf’s nucleus (S2–S4).
• → Enhances pudendal motor neuron firing.
• → Stronger urethral closure during stress (cough, laugh, run).

👉 Think: “More serotonin = stronger squeeze.”

⭐ 3. Doses You MUST Know

• Start: 20 mg once daily (to reduce nausea)
• Maintenance: 40 mg twice daily

👉 Start low → go slow (because nausea is common).

⭐ 4. Common Side Effects (Very High Yield)

• Nausea (most common → up to 20%)
• Dizziness
• Insomnia
• Dry mouth

👉 Main reason patients stop the drug = Nausea.

⭐ 5. Contraindications

Do NOT use if:

• Severe liver disease (risk of hepatotoxicity)
• Uncontrolled hypertension
• History of serotonin syndrome

👉 SNRIs ↑ BP → avoid in uncontrolled hypertension.

⭐ 6. Key Precautions

• Monitor blood pressure
• Avoid in elderly if dizziness problematic
• Avoid in severe renal impairment (eGFR <30)

👉 Monitor BP + liver → main exam point.

⭐ 7. Where Does Duloxetine Fit in Treatment?

• FIRST-LINE for SUI = pelvic floor exercises.
• Duloxetine = SECOND-LINE when exercises fail or surgery is unsuitable.

👉 It improves symptoms but is not a cure.

🔥 SUPER-SUMMARY (Memorise this to pass easily)

Duloxetine = SNRI that increases sphincter tone via pudendal nerve → used for SUI.

Start 20 mg daily → maintain 40 mg twice daily.

Common SE: Nausea, dizziness.

Avoid: Liver disease, uncontrolled hypertension.

Adjunct to pelvic floor exercises. Not curative.

Elaborative clinical scenario: Duloxetine in Stress Urinary Incontinence (SUI) — everything linked, nothing missed

A 46-year-old multiparous woman (3 vaginal deliveries) comes to clinic with 6 months of urine leakage only when she coughs, laughs, lifts heavy groceries, or runs. She says, “When I’m just sitting, I’m fine. But the moment there’s pressure, it leaks.”

1) Picking up the core concept from the history

You recognize the pattern: stress urinary incontinence — weak urethral sphincter/urethral closure that fails during rises in intra-abdominal pressure.

You confirm key negatives:

• No strong urgency preceding leakage (so not urge incontinence pattern)
• No continuous dribbling (so not fistula/overflow pattern)

So your working diagnosis is SUI (weak sphincter → poor closure during stress events).

2) First-line step (where duloxetine fits)

You explain treatment pathway clearly:

• FIRST-LINE for SUI = pelvic floor muscle training (PFMT)

You start her on supervised pelvic floor exercises and lifestyle measures.

She returns after a good trial and says:

“I did the exercises properly, but I still leak enough to affect my work and confidence.”

You discuss definitive options (including surgery), but she says she cannot commit to surgery now (or is unsuitable / prefers medical option first).

That is exactly where duloxetine fits:

• Duloxetine = SECOND-LINE when PFMT fails or surgery is unsuitable
• It can improve symptoms, but it is not a cure

3) Why duloxetine works (mechanism tied to anatomy + exam)

You explain it in a “why it works” story:

In SUI, the problem is that urethral closure pressure drops during stress. Duloxetine is helpful because it boosts the sphincter “squeeze” reflex.

• Duloxetine = SNRI (serotonin–noradrenaline reuptake inhibitor)
• By increasing serotonin + noradrenaline, it increases activity at Onuf’s nucleus (S2–S4)
• This enhances pudendal nerve motor neuron firing
• Result: increased urethral sphincter tone → stronger urethral closure during coughing/laughing/running

So you tell her in simple terms:

“Your leakage happens because the closure is weak when pressure suddenly rises. This medicine increases the nerve drive to the sphincter, so it closes tighter during stress.”

(Exam hook you can keep in mind: “More serotonin + noradrenaline at Onuf’s nucleus → pudendal nerve fires more → stronger squeeze.”)

4) Starting and titrating dose (start low → go slow)

You choose dosing to reduce drop-out:

• Start: 20 mg once daily (to reduce nausea)
• Maintenance (target): 40 mg twice daily

You explain the plan:

• “We start low to reduce side effects—especially nausea—then increase to the effective dose.”

5) Side effects (tie them to patient counseling + why patients stop)

You warn her specifically about what is most likely and most important:

Common side effects (high-yield):

• Nausea (most common; can be up to ~20%) → main reason people stop
• Dizziness
• Insomnia
• Dry mouth

You give practical counseling:

• Take after food if nauseated
• Be careful with driving/standing quickly if dizzy
• If insomnia occurs, adjust timing (clinically we often avoid late dosing)

And you explicitly set expectations:

“If nausea becomes a problem, tell us early—don’t just stop suddenly without advice.”

6) Screening for contraindications (before you prescribe)

Before writing the prescription, you check her history and baseline parameters because duloxetine is not for everyone.

You ask about liver disease and review medications/history:

• Any severe liver disease? (avoid due to hepatotoxicity risk)
• Any uncontrolled hypertension? (SNRIs can raise BP)
• Any history of serotonin syndrome? (absolute red flag)

Her BP is measured in clinic.

7) Key precautions (monitoring and special groups)

You set a safety plan and explain why:

• Monitor blood pressure (because SNRIs can increase BP)
• Be cautious in elderly if dizziness → falls risk
• Avoid in severe renal impairment (eGFR < 30)

So in her case:

• You document baseline BP and plan a BP check after dose escalation
• You check renal function if indicated (or from available records)
• You ask about dizziness risk at work/home

8) Follow-up outcome (what “success” looks like)

At follow-up after titration (reaching 40 mg BD), she reports:

• “I still leak sometimes, but it’s much less. I can work without worrying.”

You reinforce the key exam point:

• Improves symptoms but is not a cure
• Continue pelvic floor strengthening alongside medication
• Revisit surgical options later if needed

If you want, I can also convert this into an OSCE-style script (history → diagnosis → counseling → prescription + safety checks) exactly like an examiner expects.

✅ OTHER DRUGS IN STRESS URINARY INCONTINENCE (SUI)

(besides Duloxetine)

Stress incontinence = urethral sphincter weakness.

→ Drug treatment is limited because most agents are not very effective.

→ Pelvic floor exercises = FIRST LINE.

→ Surgery = most effective.

→ Drugs are used only when exercises fail or surgery is unsuitable.

⭐ 1. α-Adrenergic Agonists (Sympathomimetics)

(increase urethral sphincter tone)

Pseudoephedrine

• MOA: Stimulates α-receptors → increases urethral closure pressure
• Use: Mild SUI
• Dose: 30–60 mg 2–3 times/day
• Side effects: Hypertension, palpitations, anxiety, insomnia

Midodrine

• MOA: α-agonist → increases smooth muscle tone in bladder neck
• Use: SUI (off-label)
• Side effects: Hypertension, urinary retention, goosebumps (piloerection)

👉 Exam line: α-agonists help by tightening the bladder neck.

⭐ 2. Topical Vaginal Estrogen

(for post-menopausal women)

• Improves urethral mucosal coaptation
• Increases vascularity & sensitivity of urethra
• Best for: SUI + vaginal atrophy
• Forms: cream, ring, tablet
• Not effective as monotherapy in young women.

👉 Think: post-menopause dryness → weak mucosa → estrogen helps seal the urethra.

⭐ 3. Imipramine

(TCA – weak dual action)

• MOA:
• Mild α-agonist → increases urethral resistance
• Mild anticholinergic → relaxes detrusor
• Use: Mixed incontinence (urge + stress)
• Side effects: sedation, dry mouth, arrhythmias

👉 Used mostly in mixed incontinence, NOT pure SUI.

⭐ 4. Local Bulking Agents (not drugs but pharmacologic concept)

(Used when surgery not desired)

Examples:

• Collagen
• Carbon-coated beads
• Polyacrylamide hydrogel

MOA:

• Injected around urethra → increase coaptation → less leakage.

👉 Short-term relief, needs repeat injections.

⭐ 5. Hormone Therapy (Selective Estrogen Receptor Modulators – SERMs)

(Rare, experimental)

Ospemifene

• Improves vaginal epithelium & urethral support
• Limited evidence for SUI
• More used for dyspareunia in menopause.

🔥 SUPER-SUMMARY TO MEMORISE (Exam-High Yield)

Drugs that help SUI:

• Duloxetine (most effective medication)
• Pseudoephedrine (α-agonist → ↑ sphincter tone)
• Midodrine (α-agonist)
• Topical estrogen (postmenopausal women)
• Imipramine (mixed incontinence)
• Bulking agent injections (non-drug adjunct)

Concept: All work by strengthening urethral closure.

But overall → limited benefit. Surgery works better.

🧠🔥 COMPLETE EXAM BLOCK — URINARY INCONTINENCE )

(This is the block you revise the night before the exam)

🔑 STEP 1 — IDENTIFY THE TYPE (HISTORY = DIAGNOSIS)

URGE INCONTINENCE

• Symptoms:
• Urgency
• Frequency
• Nocturia
• Sudden urge leakage
• Pathology: Detrusor overactivity

STRESS URINARY INCONTINENCE (SUI)

• Symptoms:
• Leakage with cough, laugh, sneeze, run, lift
• Dry when resting
• Pathology: Weak urethral sphincter

MIXED INCONTINENCE

• Features of both urge + stress

👉 Exam trap: Do NOT treat before identifying the type.

🔑 STEP 2 — FIRST-LINE = AUTOMATIC ANSWER

URGE INCONTINENCE

• First-line drugs: ANTIMUSCARINICS
• Oxybutynin
• Tolterodine
• Solifenacin (preferred)

STRESS INCONTINENCE

• First-line treatment: Pelvic floor muscle training
• First-line DRUG: ❌ None

🔑 STEP 3 — CORE DRUGS + MECHANISMS (MCQ GOLD)

🔹 ANTIMUSCARINICS (URGE INCONTINENCE)

Oxybutynin / Tolterodine / Solifenacin

• MOA:

M3 muscarinic receptor blockade → detrusor relaxation

• Effects:
• ↓ involuntary bladder contractions
• ↑ bladder capacity
• ↓ urgency & urge leakage

🔹 SOLIFENACIN (EXAM FAVOURITE DETAIL)

• Class: M3-selective antimuscarinic
• Dose:
• Start 5 mg OD
• Max 10 mg OD
• Why preferred:
• M3-selective → ↓ CNS & salivary effects
• Once-daily dosing
• Extra exam point: ⚠️ QT prolongation (dose-related)

🔹 MIRABEGRON (ALTERNATIVE)

• Class: β3-agonist
• MOA:

β3 stimulation → detrusor relaxation

• Use:
• Antimuscarinic intolerance
• Elderly with cognitive risk
• Key exam point: No anticholinergic side effects,be cautious in hypertension

🔹 DULOXETINE (for STRESS INCONTINENCE)

• Class: SNRI
• MOA (must write this):
• ↑ serotonin & noradrenaline at Onuf’s nucleus (S2–S4)
• ↑ pudendal nerve firing
• ↑ urethral sphincter tone
• Dose:
• Start 20 mg OD
• Maintain 40 mg BD
• Role:
• Second-line (after PFMT)
• Not curative

🔑 STEP 4 — SIDE EFFECTS (VERY HIGH YIELD)

ANTIMUSCARINICS

• DRY + SLOW
• Dry mouth
• Constipation
• Blurred vision
• Cognitive impairment (elderly)

🚫 Contraindications:

• Urinary retention
• Gastric retention
• Narrow-angle glaucoma

SOLIFENACIN – EXTRA

• Same anticholinergic effects (less severe)
• ⚠️ QT prolongation

DULOXETINE

• Nausea (MOST COMMON, exam favourite)
• Dizziness
• Insomnia
• Dry mouth

🚫 Avoid in:

• Severe liver disease
• Uncontrolled hypertension
• Serotonin syndrome history

🔑 STEP 5 — OTHER DRUGS IN SUI (LOW-YIELD BUT EXAMINABLE)

α-Adrenergic Agonists

• Pseudoephedrine
• Midodrine
• MOA: ↑ urethral closure pressure
• SE: Hypertension, palpitations

Topical Vaginal Estrogen

• Post-menopausal women
• Improves urethral mucosal coaptation

Imipramine

• Mild α-agonist + anticholinergic
• Use: Mixed incontinence

Bulking Agents (Injected)

• Collagen, polyacrylamide gel
• Short-term benefit

🔑 STEP 6 — EXAM COMPARISON TABLE (MEMORISE)

🔥 FINAL EXAM LOCK (WRITE THIS VERBATIM IF STUCK)

• Urge incontinence is due to detrusor overactivity and is treated first-line with antimuscarinics (oxybutynin, tolterodine, solifenacin).
• Solifenacin is M3-selective, once daily, and better tolerated.
• Mirabegron is used when anticholinergic side effects limit therapy.
• Stress urinary incontinence is due to urethral sphincter weakness; pelvic floor exercises are first-line, and duloxetine improves symptoms by increasing pudendal nerve-mediated sphincter tone, but is not curative.